The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Allakos, Inc. | Common | 01671P100 | 27,861 | 4,887,932 | SH | OTR | 3,349,223 | 1,538,709 | 0 | ||
| Spruce Bioscience, Inc. | Common | 85209E109 | 4,318 | 2,148,281 | SH | SOLE | 2,148,281 | 0 | 0 | ||
| Vapotherm, Inc. | Common | 922107107 | 5,660 | 407,166 | SH | OTR | 0 | 407,166 | 0 | ||
| Mirum Pharmaceuticals, Inc. | Common | 604749101 | 42,303 | 1,921,118 | SH | SOLE | 1,921,118 | 0 | 0 | ||
| Reneo Pharmaceuticals, Inc. | Common | 75974E103 | 7,083 | 2,409,220 | SH | SOLE | 2,409,220 | 0 | 0 | ||
| Xilio Therapeutics Fund 4 | Common | 98422T100 | 10,191 | 1,441,444 | SH | SOLE | 1,441,444 | 0 | 0 | ||